MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why KARD Stock surged +4.22% Today — RQD Quant Desk Flash
$14.31 +4.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $14.39
Kardigan Inc. (KARD) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $1.34B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $14.39 (+0.57%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+1.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KARD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (61/100 Composite)
🔍 WHY KARD SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)
FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 48.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+14/20 pts (23% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$14.67-11.2% Next Q
69
Q2 (-2Q)Grade B-$13.03-1.8% Next Q
66
Q3 (-1Q)Grade C+$12.80+11.8% Next Q
64
CurrentGrade C-$14.31+0.5% Hist 90D α
61
Trajectory: B- (69) → C- (61)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the KARD Bull Thesis Could Fail
Even with a 61/100 (C-) score, KARD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($16.33) or 200D SMA ($18.98) invalidates the momentum regime and cuts Target Base ($14.50) toward Bear Floor ($11.31).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $KARD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KARD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KARD Stock surged +4.22% Today — RQD Quant Desk Flash
Kardigan Inc. (KARD) surged +4.22% to $14.31, trading at 14% of its 52-week range ($12.23 – $27). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 14% of its 52-week range ($12.23 – $27) with RSI-14 at 48.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $14.31 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $37.5M annual free cash flow.
Live KARD Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (KARD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KARD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.95%▼ DESCENDING CHANNEL
2026-10-30O $14.25H $14.65L $13.75C $14.31VOL 452.8K
RES: $18.51SUP: $9.68SMA50: $16.33SMA200: $18.98
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KARD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on KARD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KARD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KARD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KARD)
Health Care Rank #186 of 1016
⚔️ NKTR vs KARD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KARD vs. NKTR, DMRA, OMER, KRSA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Kardigan Inc. (KARD) ranks #186 by composite RQD confidence (61/100, grade C-) and #321 by equity capitalization ($1.34B). Within this direct 5-issuer industry benchmark cohort, KARD leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KARD
ACTIVE
Kardigan Inc. | C- | 61/100 | — | — | — | +4.22% | $1.34B | Benchmark Subject |
| NKTR Nektar Therapeutics | E | 33/100 | — | 96.0% | -35.0% | +1.63% | $1.34B | /nktr-vs-kard → |
| DMRA Damora Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +1.85% | $1.36B | /dmra-vs-kard → |
| OMER Omeros Corporation | D | 46/100 | — | — | -35.0% | +5.98% | $1.37B | /omer-vs-kard → |
| KRSA Korsana Biosciences Inc. | E | 33/100 | — | — | -5.7% | +0.37% | $1.38B | /krsa-vs-kard → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002123613In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kardigan Inc. (KARD) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KARD closed FY2025 with $390.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $390.9M | — |
3. KARD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Kardigan Inc. (NASDAQ: KARD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $14.31 (+4.22% 1D, market cap $1.34B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KARD ranks #186 in composite RQD confidence.
How does KARD compare to NKTR and DMRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KARD carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NKTR (Nektar Therapeutics) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.34B) and DMRA (Damora Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.36B). Among the 5-stock peer group, KARD leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KARD?
Per KARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002123613), Kardigan Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $390.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KARD trading relative to its 50-day, 200-day, and 52-week technical levels?
KARD last traded at $14.31 (+4.22% on volume of 446,399 shares), positioning the stock -12.37% below its 50-day simple moving average ($16.33) and -24.60% below its 200-day simple moving average ($18.98). Across its 52-week range of $12.23 to $27.00, KARD sits at the 14.1% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.52 to $16.10).
KARD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is KARD stock moving today?
Why KARD Stock surged +4.22% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.